Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026
Go back to Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026| ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) | Delayed: 32.37 +1.99 (6.55%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $30.38 | 52 Week High | $5.17 | |||
| Open | $30.52 | 52 Week Low | $0.94 | |||
| Day High | $32.90 | P/E | N/A | |||
| Day Low | $30.52 | EPS | $0.00 | |||
| Volume | 3,323,471 | |||||
